Publications

Authors:

Paiella, Salvatore; Landoni, Luca; De Pastena, Matteo; Elio, Giovanni; Casciani, Fabio; Cingarlini, Sara; D'Onofrio, Mirko; Maistri, Giulia; Ciatti, Ivan; Tuveri, Massimiliano; Davì, Maria Vittoria; Luchini, Claudio; Donadello, Katia; Manzini, Gessica; Malleo, Giuseppe; Salvia, Roberto

Title:

Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center

Year:

2024

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Referee:

No

Name of journal:

UPDATES IN SURGERY

ISSN of journal:

2038-131X

Page numbers:

N/A-N/A

Keyword:

COVID-19; Pancreatic neuroendocrine tumors; Pancreatic surgery; Pancreatic tumors; SARS-CoV2

Short description of contents:

: During the COVID-19 pandemic, pancreatic surgery for pancreatic neuroendocrine tumors (PNETs) with surgical indications was postponed or canceled. Patients with PNET patients who underwent pancreatic surgery during the COVID-19 restriction period (3 years) were compared with a similar cohort of patients who underwent surgery in the previous 3 years. Data on patients' characteristics, waiting time, and surgical and pathology outcomes were evaluated. During the study period, 370 patients received surgery for PNETs, 205 (55%) during the first period, and 165 (45%) during the pandemic. A lengthening of the waiting list (182 [IQR 100-357] vs. 60 [40-88] days, p < 0.001) and increased use of anti-tumor medical treatments (any therapy, peptide receptor radionuclide therapy, and somatostatin analogs; all p < 0.001) was found. During the pandemic, surgery occurred after a median of 381 days [IQR 200-610] from diagnosis (vs. 103 [IQR 52-192] of the pre-COVID-19 period, p < 0.001). No statistically significant differences in tumor size and grading distribution were found between the two periods (both p > 0.05), yet only a modest increase of the median Ki67 values in cases operated during the pandemic (4% vs. 3%, p = 0.03). Lastly, these latter patients experienced less major postoperative complications (13% vs. 24%, p = 0.007). During COVID-19, the surgical waiting list of PNET patients was drastically extended, and bridge therapies were preferred. This did not result in more advanced cases at final pathology. PRRT and SSA are valid alternative therapies for PNETs when surgery is not feasible.

Product ID:

140594

Handle IRIS:

11562/1131806

Last Modified:

July 24, 2024

Bibliographic citation:

Paiella, Salvatore; Landoni, Luca; De Pastena, Matteo; Elio, Giovanni; Casciani, Fabio; Cingarlini, Sara; D'Onofrio, Mirko; Maistri, Giulia; Ciatti, Ivan; Tuveri, Massimiliano; Davì, Maria Vittoria; Luchini, Claudio; Donadello, Katia; Manzini, Gessica; Malleo, Giuseppe; Salvia, Roberto, Surgery for pancreatic neuroendocrine tumors during the COVID-19 pandemic: a retrospective cohort from a high-volume center «UPDATES IN SURGERY» , 2024 , pp. N/A-N/A

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo